Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

24 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Mecamylamine Articles

AGI's CID drug shows benefit at higher dose

23 March 2009

AGI's loss deepens on flat revenue

22 September 2008

AGI begins dosing in Ph II CID trial

11 February 2008

Targacept to advance drug into clinicals

29 October 2007

R&D costs double AGI's 1st-half loss

24 September 2007

Targacept announces positive mecamylamine HCl data

30 July 2007

CoMentis starts Ph II AMD study

16 April 2007

AGI reports good initial results from two Ph II trials

5 February 2007

Targacept's TRIDMAC improves on Celexa

20 November 2006

Anti-alcohol consumption patch in development

26 April 2004

Mecamylamine promising in Tourette syndrome

13 July 2000

Layton BioScience to look at Inversine in neurological diseases

18 May 2000

Elan's Combi Nicotine Patch A Partial Success

24 November 1998

Elan Acquires Sano In Deal Valued At $375 Million

17 December 1997

Sano Anxiety Patch Enters Ph III

3 March 1997

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Italy's pharma market slump set to continue, warns GlobalData
  • US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Italy's pharma market slump set to continue, warns GlobalData

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS